研究人員正在尋找治療某些類型晚期實體瘤的新方法。實體瘤是指主要位於身體器官和組織中的癌症，而非血液或其他體液中的癌症。晚期可能意味著癌症已擴散至附近或身體其他部位。該癌症可能無法以手術或放射治療（利用高能量射束，如X光，來縮小或消除腫瘤）來治療。
適應症：Advanced Solid Tumors、Malignant Neoplasm
收案條件
納入條件
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- If human immunodeficiency virus (HIV)-infected, has well-controlled HIV on antiretroviral therapy (ART)
- If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy for at least 4 weeks
- If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load
- Has adequate organ function
排除條件
- If prior anticancer therapy is allowed, participants are excluded if they received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before allocation
- Has received prior locoregional therapy within 2 weeks of start of study intervention, or has ongoing locoregional treatment-related toxicities
- Is currently receiving any anticoagulants
- Was discontinued from prior immunotherapy due to a Grade ≥3 immune-related adverse event (irAE)
- Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- Has known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has active autoimmune disease that has required systemic treatment in the past 2 years
- Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments
- Active or ongoing stomatitis and/or mucositis of any grade
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis
- Has history of posterior reversible encephalopathy syndrome (PRES) or seizure disorder
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- Has history of stem cell/solid organ transplant
- Has not adequately recovered from major surgery or from central venous access device placement, or has ongoing surgical complications
- Has clinically significant hemoptysis, hematemesis, or tumor bleeding within 4 weeks before the first dose of study intervention
- Has any clinically significant or life-threatening bleeding event that occurred within 3 months prior to the first dose of the study intervention
- Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
- Has any history of myocarditis or cardiomyopathy
- Has a current or history of severe cardiovascular and cerebrovascular diseases
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年11月5日。